Dara Azar
Stock Analyst at Stifel Nicolaus
(3.21)
# 2,579
Out of 4,690 analysts
18
Total ratings
63.6%
Success rate
17.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dara Azar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INBX Inhibrx Biosciences | Maintained: Buy | $325 | $123.85 | +162.41% | 7 | Aug 21, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $82 | $57.86 | +41.72% | 4 | Aug 13, 2026 | |
| SMMT Summit Therapeutics | Maintained: Buy | $38 | $13.73 | +176.77% | 7 | Jul 28, 2026 |
Inhibrx Biosciences
Aug 21, 2026
Maintained: Buy
Price Target: $325
Current: $123.85
Upside: +162.41%
Enliven Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $82
Current: $57.86
Upside: +41.72%
Summit Therapeutics
Jul 28, 2026
Maintained: Buy
Price Target: $38
Current: $13.73
Upside: +176.77%